Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol.
about
Plasma membrane cytoskeleton of muscle: a fine structural analysis.Novel approaches to treat muscular dystrophies.Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-α2-deficient mouse model of congenital muscular dystrophy.The muscular dystrophies: from genes to therapies.cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regenerationTowards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyPathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophyRole of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy.Gene expression profiling of diaphragm muscle in alpha2-laminin (merosin)-deficient dy/dy dystrophic mice.The effects of muscular dystrophy on the craniofacial shape of Mus musculus.Sternohyoid muscle fatigue properties of dy/dy dystrophic mice, an animal model of merosin-deficient congenital muscular dystrophy.Alteration of contractile force and mass in the senescent diaphragm with beta(2)-agonist treatment.Myotoxic effects of clenbuterol in the rat heart and soleus muscle.Changes in muscle proteins and spermidine content in response to unloading and clenbuterol treatment.Clenbuterol Induces Cell Cycle Arrest in C2C12 Myoblasts by Delaying p27 Degradation through β-arrestin 2 Signaling.Isotonic contractile impairment due to genetic CLC-1 chloride channel deficiency in myotonic mouse diaphragm muscle.
P2860
Q33840927-AA38A634-6E22-4487-8887-0A8AA9CD1153Q34204364-F187C962-3D40-422B-9696-DE4FB4ACCAB0Q35030852-78F3CA2B-B070-4C63-BE8F-8B39EF718858Q35834674-1312FDA3-F4E3-424A-946A-20E1CEC8D4D3Q36114861-A0627EA2-F699-42AD-A4BC-F290BBC473F9Q36841572-3C848226-519B-48B2-82E7-5386A7C65185Q37091285-2C316AFE-2A0C-49B9-BFB7-2AC75BEF28AFQ37129351-DCEAE1D5-9E54-4341-B844-B1D5259F9780Q37625936-9579103F-269B-44FC-B5B4-25B9CA19519AQ38317471-22C884F8-02D4-4CF4-BC52-C333CAAA1A83Q40219721-2AEE31AB-DC58-4FFD-9E92-C97B23E34D1BQ42163677-C5D52954-FB34-4C9C-9EB7-15D6ACC2C409Q43884284-7884C5E5-1CA1-49FF-8AA5-882655124F1DQ44180856-F5650DE4-8E9F-4AF3-A258-4F65F9DB5C39Q44382640-0AF725FB-BBE4-47B4-8470-390E737D3883Q44510653-771F4838-D4EE-4AFC-912C-1BC09A8B93E8Q51915609-E0F29C34-5F52-4ED6-8EA4-EAD5710462AC
P2860
Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Examining potential drug thera ...... e dy/dy mouse: I. Clenbuterol.
@en
Examining potential drug thera ...... e dy/dy mouse: I. Clenbuterol.
@nl
type
label
Examining potential drug thera ...... e dy/dy mouse: I. Clenbuterol.
@en
Examining potential drug thera ...... e dy/dy mouse: I. Clenbuterol.
@nl
prefLabel
Examining potential drug thera ...... e dy/dy mouse: I. Clenbuterol.
@en
Examining potential drug thera ...... e dy/dy mouse: I. Clenbuterol.
@nl
P1476
Examining potential drug thera ...... e dy/dy mouse: I. Clenbuterol.
@en
P2093
Williams DA
P304
P356
10.1016/S0022-510X(98)00084-7
P50
P577
1998-05-01T00:00:00Z